Suxiao Jiuxin Pills in Microvascular Obstruction in Patients With Acute Coronary Syndrome

Inclusion Criteria:

• Meet the diagnosis of AMI, prepare for PCI reperfusion therapy;
• Between the ages of 18-75;
• Volunteer to participate in this study and have signed an informed consent form;
• Have a correct understanding of the significance of drug research, and have a goodcompliance with the observation and evaluation.

Exclusion Criteria:

• Not suitable for coronary intervention;
• With unstable hemodynamics;
• Platelet count<100×109;
• Suspected aortic dissection or acute pulmonary embolism;
• With mechanical complications;
• With uncontrolled acute left heart failure and pulmonary edema;
• With known bleeding history, active bleeding, bleeding constitution, or severehemostatic and coagulation dysfunction;
• Meantain anticoagulants (such as warfarin or new anticoagulants);
• Severe liver and kidney insufficiency (Child-Pugh B and above, Cr>177μmol/L (2mg/dl)or eGFR<45ml/min/1.73m2);
• CTO, stent stenosis, or severe left main disease;
• History of coronary artery bypass graft surgery;
• Other pathophysiological conditions whose expected survival period is less than 1year;
• Allergic history to Suxiao Jiuxin Pills;
• Pregnant or lactating women;
• Participating in other clinical studies;
• With other diseases that are not suitable for participating in clinical research.